ABIOMED, Inc. (ABMD)
(Delayed Data from NSDQ)
$271.75 USD
+6.98 (2.64%)
Updated May 3, 2019 04:00 PM ET
After-Market: $271.72 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$271.75 USD
+6.98 (2.64%)
Updated May 3, 2019 04:00 PM ET
After-Market: $271.72 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
3 Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Why Is Abiomed (ABMD) Up 1.2% Since Last Earnings Report?
by Zacks Equity Research
Abiomed (ABMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold on to Abiomed (ABMD) Stock Now
by Zacks Equity Research
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Is Molina Healthcare (MOH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Molina (MOH) and Abiomed (ABMD) have performed compared to their sector so far this year.
Company News for Nov 2, 2022
by Zacks Equity Research
Companies in The News Are: ABMD,ARCB,MPC,TAP
ABIOMED, Inc. (ABMD) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Abiomed (ABMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
3 Stocks That Popped Yesterday
by Sejuti Banerjea
We're in the middle of earnings season, so it would be natural to assume that earnings reports are the biggest drivers of stocks during the season. But that isn't the case with a bunch that soared yesterday.
Pre-Markets in Green to Start a Fresh Month
by Zacks Equity Research
Pre-Markets in Green to Start a Fresh Month
Abiomed (ABMD) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Abiomed's (ABMD) strength in Impella product revenues drives its Q2 top line.
Pre-Markets Up Ahead of New Fed Hike, Q3 Beats
by Mark Vickery
Big Pharma giants Pfizer (PFE) and Lilly (LLY) posted beats on both top and bottom lines this morning, while J&J (JNJ) is buying Abiomed (ABMD).
Abiomed (ABMD) Beats Q2 Earnings Estimates
by Zacks Equity Research
Abiomed (ABMD) delivered earnings and revenue surprises of 23.81% and 2.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks Due to Report Earnings on Nov 1: MCK, CTLT & More
by Debanjana Dey
MedTech companies' Q3 results are likely to reflect strength in customer demand. Let's see how MCK, CTLT, ECL, ABMD, HSIC and IDXX are placed ahead of their earnings releases.
Is Abiomed (ABMD) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Abiomed (ABMD) possesses solid growth attributes, which could help it handily outperform the market.
The Zacks Analyst Blog Highlights Nevro, Masimo, Abiomed and Glaukos
by Zacks Equity Research
Nevro, Masimo, Abiomed and Glaukos are part of the Zacks top Analyst Blog.
4 MedTech Stocks Set to Outpace Q3 Earnings Estimates
by Indrajit Bandyopadhyay
Let us take a look at some MedTech stocks, NVRO, MASI, ABMD and GKOS, which are poised to beat on third-quarter earnings.
Earnings Preview: Inari Medical, Inc. (NARI) Q3 Earnings Expected to Decline
by Zacks Equity Research
Inari Medical, Inc. (NARI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Abiomed (ABMD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Abiomed (ABMD) stock based on the movements in the options market lately.
McKesson (MCK) to Report Q2 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
McKesson's (MCK) fiscal second-quarter results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
Abiomed (ABMD) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven Q2 sales.
Abiomed (ABMD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Abiomed (ABMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Molina Healthcare (MOH) to Post Q3 Earnings: What to Expect
by Zacks Equity Research
Molina Healthcare's (MOH) Q3 results are expected to reflect better premiums and membership growth in its Medicaid and Medicare businesses, partly offset by steep general and administrative costs.
Abiomed's (ABMD) Latest Impella Offering Approved by the FDA
by Zacks Equity Research
Abiomed's (ABMD) latest regulatory clearance for the Impella Low Profile Sheath is expected to improve patient outcomes.